INS and type 1 diabetes mellitus: In a multicenter prospective cohort study comparing continuous subcutaneous insulin infusion (CSII) to multiple daily injections (MDI) in women with pregestational type 1 diabetes mellitus (T1DM), CSII users achieved better glycaemic control in the third trimester, showing a lower HbA1c and a higher rate of HbA1c within target range compared to those on MDI [9] Real-world data further support the efficacy of AID systems, with a substantial proportion of users achieving glycaemic targets and improved time-in-range metrics [10].